Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $138,910.58 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 12,946 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $10.73, for a total value of $138,910.58. Following the sale, the executive vice president now owns 722,128 shares of the company’s stock, valued at approximately $7,748,433.44. This represents a 1.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

David Sponsel also recently made the following trade(s):

• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The shares were sold at an average price of $11.42, for a total value of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The shares were sold at an average price of $10.71, for a total value of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The shares were sold at an average price of $10.00, for a total value of $2,380.00.

Alphatec Trading Up 3.4 %

Shares of Alphatec stock opened at $12.53 on Friday. The firm has a market capitalization of $1.78 billion, a PE ratio of -9.79 and a beta of 1.43. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $14.88. The firm’s 50-day moving average price is $10.63 and its 200 day moving average price is $8.37. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The company had revenue of $176.79 million during the quarter, compared to analysts’ expectations of $172.74 million. On average, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Trading of Alphatec

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. PharVision Advisers LLC acquired a new stake in shares of Alphatec during the 4th quarter worth approximately $201,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Alphatec by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 224,643 shares of the medical technology company’s stock worth $2,062,000 after buying an additional 22,971 shares during the last quarter. Western Standard LLC acquired a new stake in shares of Alphatec during the 4th quarter worth approximately $6,668,000. Soviero Asset Management LP acquired a new stake in Alphatec in the 4th quarter valued at approximately $918,000. Finally, Wexford Capital LP acquired a new stake in Alphatec in the 4th quarter valued at approximately $95,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Analyst Ratings Changes

ATEC has been the topic of several research reports. Piper Sandler upped their target price on Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Alphatec in a research report on Thursday. StockNews.com raised Alphatec from a “sell” rating to a “hold” rating in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. Finally, Barclays upped their target price on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.